JP2013518867A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518867A5 JP2013518867A5 JP2012551673A JP2012551673A JP2013518867A5 JP 2013518867 A5 JP2013518867 A5 JP 2013518867A5 JP 2012551673 A JP2012551673 A JP 2012551673A JP 2012551673 A JP2012551673 A JP 2012551673A JP 2013518867 A5 JP2013518867 A5 JP 2013518867A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- pharmaceutical composition
- treatment
- organic amine
- salt according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 63
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 150000001412 amines Chemical class 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 230000000813 microbial effect Effects 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- IKXCHOUDIPZROZ-LXGUWJNJSA-N (2r,3r,4r,5s)-6-(ethylamino)hexane-1,2,3,4,5-pentol Chemical group CCNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO IKXCHOUDIPZROZ-LXGUWJNJSA-N 0.000 claims description 4
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 4
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 241000193163 Clostridioides difficile Species 0.000 claims description 2
- 241000194032 Enterococcus faecalis Species 0.000 claims description 2
- 241000194031 Enterococcus faecium Species 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- -1 amine compound Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical group OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- MDSUKZSLOATHMH-IUCAKERBSA-N Leu-Val Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C([O-])=O MDSUKZSLOATHMH-IUCAKERBSA-N 0.000 claims 2
- MDSUKZSLOATHMH-UHFFFAOYSA-N N-L-leucyl-L-valine Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(O)=O MDSUKZSLOATHMH-UHFFFAOYSA-N 0.000 claims 2
- PNVLWFYAPWAQMU-CIUDSAMLSA-N Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)C(C)C PNVLWFYAPWAQMU-CIUDSAMLSA-N 0.000 claims 2
- 210000004872 soft tissue Anatomy 0.000 claims 2
- ICIJWOWQUHHETJ-UHFFFAOYSA-N (3,5-dichlorophenyl)methanamine Chemical compound NCC1=CC(Cl)=CC(Cl)=C1 ICIJWOWQUHHETJ-UHFFFAOYSA-N 0.000 claims 1
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 241000032203 Conus aureus Species 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 108010053762 deoxyactagardine B Proteins 0.000 claims 1
- 208000027136 gram-positive bacterial infections Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GC2010/15215 | 2010-02-02 | ||
| PCT/GB2010/000188 WO2010089544A1 (en) | 2009-02-04 | 2010-02-02 | Actagardine derivatives |
| TW099103071 | 2010-02-02 | ||
| GCP201015215 | 2010-02-02 | ||
| TW099103071A TWI504610B (zh) | 2009-02-04 | 2010-02-02 | 阿肽加定衍生物、其製備方法及其用途 |
| GBPCT/GB2010/000188 | 2010-02-02 | ||
| GB1013511.9 | 2010-08-11 | ||
| GBGB1013511.9A GB201013511D0 (en) | 2010-08-11 | 2010-08-11 | Salts |
| PCT/GB2011/000133 WO2011095768A1 (en) | 2010-02-02 | 2011-02-01 | Lantibiotic salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518867A JP2013518867A (ja) | 2013-05-23 |
| JP2013518867A5 true JP2013518867A5 (enExample) | 2014-03-20 |
| JP5852966B2 JP5852966B2 (ja) | 2016-02-03 |
Family
ID=46759960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012551673A Expired - Fee Related JP5852966B2 (ja) | 2010-02-02 | 2011-02-01 | ランチビオティックの塩 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120309676A1 (enExample) |
| EP (1) | EP2531519A1 (enExample) |
| JP (1) | JP5852966B2 (enExample) |
| CA (1) | CA2789164A1 (enExample) |
| MX (1) | MX2012008819A (enExample) |
| TW (1) | TW201138800A (enExample) |
| WO (1) | WO2011095768A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201001688D0 (en) | 2010-02-02 | 2010-03-17 | Novacta Biosystems Ltd | Compounds |
| GB201013513D0 (en) * | 2010-08-11 | 2010-09-22 | Novacta Biosystems Ltd | Formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1013511A (en) | 1963-01-31 | 1965-12-15 | Decca Ltd | Improvements in or relating to systems for steering an electric current to a selected |
| GB8507528D0 (en) | 1985-03-22 | 1985-05-01 | Lepetit Spa | Basis monocarboxyamide derivatives |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| DE60105023T2 (de) | 2000-06-28 | 2005-08-18 | Smithkline Beecham P.L.C., Brentford | Nassvermahlungsverfahren |
| US7034113B2 (en) * | 2002-02-22 | 2006-04-25 | Paradigm Diagnostics, Llc | Bacteriocin-metal complexes in the detection of pathogens and other biological analytes |
| GB0600928D0 (en) * | 2006-01-17 | 2006-02-22 | Novacta Biosystems Ltd | Improvements relating to lantibiotics |
| GB0714030D0 (en) * | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | The use of type-B lantibiotic-based compounds having antimicrobial activity |
| GB0714029D0 (en) * | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | Lantibiotic-based compounds having antimicrobial activity |
| DE102008036269A1 (de) | 2008-08-04 | 2010-02-11 | Ewe Ag | Vorrichtung zum kontinuierlichen Mischen von ausgespeichertem Erdgas mit Sauerstoff zu einem Brenngas für eine Erwärmung des unter Druck stehenden Erdgases vor oder nach seiner Entspannung |
| CN102388060B (zh) * | 2009-02-04 | 2014-09-10 | 诺瓦克塔生物系统有限公司 | 阿肽加定衍生物 |
-
2011
- 2011-02-01 EP EP11705953A patent/EP2531519A1/en not_active Withdrawn
- 2011-02-01 US US13/576,892 patent/US20120309676A1/en not_active Abandoned
- 2011-02-01 JP JP2012551673A patent/JP5852966B2/ja not_active Expired - Fee Related
- 2011-02-01 TW TW100104046A patent/TW201138800A/zh unknown
- 2011-02-01 WO PCT/GB2011/000133 patent/WO2011095768A1/en not_active Ceased
- 2011-02-01 CA CA2789164A patent/CA2789164A1/en not_active Abandoned
- 2011-02-01 MX MX2012008819A patent/MX2012008819A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5756495B2 (ja) | ペプチドおよびその使用 | |
| JP2013014613A (ja) | 細菌感染症を治療するためのダルババンシン組成物 | |
| JP5805389B2 (ja) | 非経口用抗菌剤 | |
| WO2013040528A1 (en) | Antimicrobial compounds | |
| JP2016529325A (ja) | 抗微生物化合物ならびにそれの製造方法および使用方法 | |
| TW201028161A (en) | Novel antibacterial agents for the treatment of gram positive infections | |
| TWI335332B (en) | Cross-linked vancomycin-cephalosporin antibiotics | |
| JP6142076B2 (ja) | 抗微生物性増強剤 | |
| TWI325323B (en) | Cross-linked glycopeptide-cephalosporin antibiotics | |
| ES2858431T3 (es) | Purificación de pleuromutilina | |
| JP2014531431A (ja) | キサントン化合物の誘導体 | |
| CN102180890B (zh) | 头孢硫脒结晶物及其用途 | |
| WO2020117755A1 (en) | Compositions and methods for treating biofilms | |
| JP2013518867A5 (enExample) | ||
| JP2024009968A5 (enExample) | ||
| CN110612306A (zh) | 新缩肽类及其用途 | |
| CA2949328C (en) | Low substituted polymyxins and compositions thereof | |
| TW200848062A (en) | Semi-synthetic glycopeptides with antibacterial activity | |
| JP2021510148A (ja) | 新規抗生物質およびその使用方法 | |
| JP2017514887A (ja) | 抗菌性コンジュゲート、その製造方法及び使用 | |
| CN107106533B (zh) | 用于治疗微生物感染的增效组合物 | |
| US20240261256A1 (en) | Methods of treating bacterial infections | |
| CN112107676B (zh) | 一种脂肽及其在抗菌中的应用 | |
| JP6441229B2 (ja) | 抗菌化合物 | |
| US8664240B2 (en) | R-7-(3-aminomethyl-4-methoxyimino-3-methyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid and L-aspartic acid salt, process for the preparation thereof and pharmaceutical composition comprising the same for antimicrobial |